Sensus Healthcare to Announce Fourth Quarter and Full Year 2016 Results on February 2, 2017
BOCA RATON, Fla., Jan. 19, 2017 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today announced that it will report its fourth quarter and full year 2016 financial results on Thursday, February 2, 2017 […]
SRT-100™: The Doctor’s Choice for Treatment of Non-Melanoma Basal Cell Cancer
Giving a skin cancer diagnosis to a patient is never easy. The word “cancer” is a scary word for any patient to hear. Sadly, one in five Americans will develop skin cancer over the course of their lifetime and 40 to 50 percent of Americans who live to age 65 will have either basal cell […]
Sensus Healthcare to Participate in Annual JP Morgan Healthcare Conference Week on January 9th – 11th in San Francisco
BOCA RATON, Fla., Jan. 3, 2017 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers (NMSC) and other skin conditions such as keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, CEO and Arthur Levine, CFO will participate in the Annual JP Morgan Healthcare […]
